Business Wire

Mitsubishi Heavy: H-100 Gas Turbine & Low NOx Combustion System Receives Full Mechanical Drive Qualification by Shell

Del

The industry leading 118MW H-100 gas turbine, packaged for mechanical drive applications under the partnership of Mitsubishi Heavy Industries, Ltd. (MHI)(TOKYO:7011), Mitsubishi Hitachi Power Systems, Ltd. (MHPS) and Mitsubishi Heavy Industries Compressor Corporation (MCO) has achieved full qualification status by Shell’s Technical team based in The Hague.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180312005350/en/

MHPS H-100 Gas Turbine (Photo: Business Wire)

MHPS H-100 Gas Turbine (Photo: Business Wire)

In August 2017, MHPS embarked on a rigorous testing regime to validate the mechanical drive performance of their 2-shaft 118MW H-100 Gas Turbine equipped with their low NOx (single digit ppm) combustion system. After successful completion of testing protocol and a detailed technical review by their qualification team, Shell announced their official qualification of the MHPS gas turbine on December 22, 2017. This followed Shell’s earlier qualification of the MHPS 108MW H-100 gas turbine in 2015. Shell has already qualified Mitsubishi Compressors by Enterprise Frame Agreement effective in 2011, clearing the way for MHPS and MCO to supply all components for future Shell LNG compression systems.

Upon receiving notification from Shell, MHI President & CEO Shunichi Miyanaga commented, “This milestone in the continued development of the H-100 gas turbine underscores Mitsubishi’s competitiveness as the main driver for world-scale LNG liquefaction trains and complements the H-Series strong position in the thermal power plant market. Our goal is to provide our customers with high reliability and productivity, while reducing emissions, complexity, and the overall cost of LNG production.”

The heavy-duty H-100 Gas Turbine also offers best in class efficiency and reliability with low-maintenance. Benefits of the two-shaft gas turbine for LNG mechanical drive applications include a broad variable-speed operating window, train restarts under settle-out pressure. H-100 gas turbine also adds the benefit such as shortened start-up time and a significantly reduced plot size.

Mitsubishi Heavy Industries Group will further integrate and expand the diverse product and technology lineup of its energy and oil & gas business to meet market needs.

About Mitsubishi Heavy Industries

Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, Japan, is one of the world’s leading heavy machinery manufacturers, with consolidated sales of 3,992.1 billion yen in fiscal 2014, the year ended March 31, 2015. MHI’s diverse lineup of products and services encompasses shipbuilding, power plants, chemical plants, environmental equipment, steel structures, industrial and general machinery, aircraft, space systems and air-conditioning systems. For more information, please visit the company’s website http://www.mhi-global.com/index.html

And more about MHI Oil & Gas Business: http://ceraweek.mhi.com/

About Mitsubishi Heavy Industries Compressor Corporation

Mitsubishi Heavy Industries Compressor Corporation (MCO) is a wholly-owned subsidiary of Mitsubishi Heavy Industries, Ltd. MCO is one of the worldʼs largest manufacturers of process compressors and mechanical drive steam turbines. MCO provides the design, manufacture, sales, and after-sales services of compression systems composed of compressor, drive machinery and peripheral equipment. For more information, please visit the company’s website http://www.mhicompressor.com/en/

About Mitsubishi Hitachi Power Systems

Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world's leading suppliers of equipment and services to the power generation market, Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, conventional gas/coal/oil-fired (thermal) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the company's website https://www.mhps.com/

Contact information

PRESS CONTACT:
Mitsubishi Heavy Industries, Ltd.
Joseph Hood, +81-(0)3-6716-2168
PR Manager
mhi-pr@mhi.co.jp
Fax: +81-(0)3-6716-5860

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs

Kalray Joins Autoware Foundation as Founding Premium Member14.12.2018 07:18Pressemelding

Kalray (Euronext Growth Paris – ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined the Autoware Foundation as a founding premium member. The formation of Autoware was formally announced on December 10, 2018 with a mission of facilitating the deployment of Autoware open-source projects enabling self-driving mobility. The Autoware Foundation creates synergies between corporate development and academic research, enabling autonomous driving technology for everyone. "We are glad to have the presence of Kalray as a premium member of the Autoware Foundation. Having highly efficient hardware solutions supporting autonomous driving software is instrumental to boost the deployment of Autoware in the market!" said Shinpei Kato, member of the Board of Directors for Autoware. Autonomous driving demands massive processing power, low power consumption and bulletproof safety and security to handle critical functions like AI processing, acceleration of perception

IDEMIA Provides Subscription Management Platform to dtac in Thailand to Offer eSIM Connected Watches to All Its Subscribers.14.12.2018 03:30Pressemelding

IDEMIA, the global leader in Augmented Identity, has been selected by dtac, the leading mobile operator in Thailand, to offer connectivity on eSIM connected watches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005934/en/ Credits : IDEMIA IDEMIA’s Subscription Management platform (or remote SIM provisioning) is the technology that remotely connects the embedded SIM of a smartwatch to dtac’s network without inserting a physical SIM card. Indeed, the IDEMIA Subscription Manager is a server which securely manages the lifecycle of mobile subscriptions and profiles for eSIM-ready consumer devices and wearables. This solution is compliant with the latest GSMA (Global System for Mobile Communications Association) standards to ensure global interoperability and, thanks to the scalability of the platform, the operator will be able to serve up to millions of customers during peak times. dtac subscribers now have the possibilit

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer13.12.2018 17:46Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the first quarter of 2019. Once approved, Rubraca’s indication will expand beyond its initial Marketing Authorization in Europe granted in May 2018 for adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum

Dole Food Company Sells Fresh Cut Business in Sweden and Finland13.12.2018 17:00Pressemelding

Dole Food Company, Inc., announced today an agreement to sell Saba Fresh Cuts AB and Saba Fresh Cuts OY to BAMA International. Saba Fresh Cuts AB—with production facility in Helsingborg Sweden—and Saba Fresh Cuts OY—with production facility in Espoo Finland—are producers of washed and ready-to-eat salads. The companies prepare and sell various fresh-cut salads and vegetables to the retail and foodservice industry in Sweden, Denmark, Finland, Germany and the Baltic States. The sale of Saba Fresh Cuts AB was a necessary condition of the European Commission’s approval of the investment by Total Produce into Dole in July 2018. “I am very pleased with the outcome of this sale in meeting the EU’s requirement,” said Mr. Johan Linden, President and Chief Executive Officer of Dole Food Company, “and I am confident that Saba Fresh Cuts will be in good hands under BAMA’s ownership.” "We are pleased to announce this agreement with Dole for Saba Fresh Cuts. Convenience products and ready-to-eat sal